Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicing

Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital Management LLC and Vivo Capital

SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced the closing of an $84 million Series B extension, bringing total capital raised by BlossomHill to $257 million to date. Proceeds from the financing will be used to accelerate BlossomHill's two lead clinical programs, BH-30643 (OMNI-EGFRTM inhibitor) and BH-30236 (CLK inhibitor), and to further advance the company's wholly-owned pipeline of intelligently designed cancer medicines.

The Series B extension financing included a select group of new investors, led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, and participation from existing investors including Cormorant Asset Management, OrbiMed, Plaisance Capital Management LLC and Vivo Capital.

"With clinical data beginning to come into focus across both of our lead programs, momentum is building at BlossomHill Therapeutics," said J. Jean Cui, Ph.D., President & Chief Executive Officer of BlossomHill. "We are delighted by the strong vote of confidence from new and existing investors in this financing, which arrives at a critical juncture as we drive our clinical programs forward and leverage our established track record in oncology drug design to address the challenges of cancer treatment resistance and deliver meaningful benefit for cancer patients."

Vish Sridharan, M.D., ...